A study of pharmacokinetic analysis of capecitabine and cytidine deaminase activity

A study of pharmacokinetic analysis of capecitabine and cytidine deaminase activity - A study of pharmacokinetic analysis of capecitabine and cytidine deaminase activity

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019244

Enrollment

Registered

2015-11-01

Start date

2015-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast and colorectal cancer

Interventions

Blood samples(10 points) are collected after the first administration of capecitabine for pharmacokinetic analysis and cytidine deaminase activity measurement.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically proven breast or colorectal cancer patients 2)Age>= 20 years 3)Planned to receive capecitabine 4)PS(ECOG):0-2 5)Adequate organ function white blood-cell count>= 3,000/uL hemoglobin concentration >= 9.0g/dL platelet count>= 100,000/uL 6)Life expectancy more than 3 months 7)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Patients that administration of capacitabine is contraindicated 2)Patients with administration of warfarin 3)Patients with active infections 4)Patients who judged by investigator to be inappropriate for study participation for serious psychiatric condition 5)Patients who judged by investigator to be inappropriate for study participation for any reason

Design outcomes

Primary

Measure	Time frame
To evaluate the correlation AUC of 5-DFUR/AUC of 5-DFCR ratio and cytidine deaminase activity.	—

Countries

Japan

Contacts

Public ContactTakahiro Inaishi

Nagoya University Hospital Department of Clinical Oncology and Chemotherapy

t.inaishi@med.nagoya-u.ac.jp052-744-1903

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026